New trends in cholinergic therapy for Alzheimer disease: Nicotinic agonists or cholinesterase inhibitors?

Progress in Brain Research

Volumn 109, Issue , 1996, Pages 311-323

  Giacobini, E ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORONICOTINE; ADRENERGIC RECEPTOR STIMULATING AGENT; ANABASINE; BETHANECHOL; CHOLINESTERASE INHIBITOR; CLONIDINE; DONEPEZIL; HEPTYLPHYSOSTIGMINE; IDAZOXAN; METANICOTINE; METRIFONATE; MF 268; NICOTINIC AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; PHYSOSTIGMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030464044     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0079-6123(08)62114-7     Document Type: Conference Paper

References (72)

1. J.P. Anderson L.M. Refolo W. Wallace P. Mehta M. Krishnamurthi J. Gotlib L. Bierer V. Haroutunian D. Perl N.K. Robakis Differential brain expression of the Alzheimer's amyloid precursor protein. EMBO J. 1 1989 3627 3632
2. L. Beani S. Tanganelli T. Antonelli C. Bianchi Noradrenergic modulation of cortical acetylcholine release is both direct and gamma-aminobutyric acid-mediated. J. Pharmacol. Exp. Ther. 1 1986 230 236
3. R.E. Becker E. Giacobini Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological and therapeutic aspects. Drug Dev. Res. 1 1988 163 195
4. R.E. Becker P. Moriearty L. Unni The second generation of cholinesterase inhibitors: clinical and pharmacological effects. E. Giacobini R. Becker Cholinergic Basis for Alzheimer Therapy 1991 Birkhauser Boston Cambridge, MA 263 296
5. J.G. Beeson E.R. Shelton H.W. Chan F.H. Gage Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies. J. Comp. Neurol. 1 1994 78 96
6. R.J. Beninger The role of dopamine in locomotor activity and learning. Brain Res. Rev. 1 1983 173 196
7. T.J. Brozoski R.M. Brown H.E. Rosvold P.S. Goldman Cognitive deficit caused by regional depletion of dopamine in the prefrontal cortex of rhesus monkey. Science 1 1979 929 932
8. M. Brufani M. Marta M. Pomponi Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia. Eur. J. Biochem. 1 1986 115 120
9. G. Buckley S. Consolo E. Giacobini R. McCaman A micromethod for the determination of choline acetylase in individual cells. Acta Physiol. Scand. 1 1967 341 347
10. J.D. Buxbaum M. Oishi H.I. Chen R. Pinkas-Kramarski E.A. Jaffe S.E. Gandy P. Greengard Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer βA4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA 1 1992 10075 10078
11. 2-noradrenergic system - effects on cognition. Drugs Aging 1 1994 116 126
12. G. Cuadra E. Giacobini Co-administration of cholinesterase inhibitors and idazoxan: effects of neurotransmitters in rat cortex in vivo. J. Pharmacol. Exp. Ther. 1 1995 230 240
13. G. Cuadra E. Giacoibni Effects of cholinesterase inhibitors and clonidine co-administration on rat cortex neurotransmitters in vivo. J. Pharmacol. Exp. Ther. 1 1995 228 236
14. G. Cuadra K. Summers E. Giacobini Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J. Pharmacol. Exp. Ther. 1 1994 277 284
15. M.W. Decker J.L. McGaugh The role of interactions between cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1 1991 151 168
16. S.T. De Kosky S.D. Styren M.E. O'Malley Cholinergic changes and synaptic alterations in Alzheimer's disease. E. Giacobini R. Becker Alzheimer Disease: Therapeutic Strategies 1994 Birkhauser Boston Cambridge, MA 93 98
17. 2- adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J. Pharmacol. Exp. Ther. 1 1987 642 649
18. A.Y. Deutch J. Holliday R.H. Roth L.L.Y. Chun E. Hawrot Immunohistochemical localization of a neuronal nicotinic acetylcholine receptor in mammalian brain. Proc. Natl. Acad. Sci. USA 1 1987 8697 8701
19. G. Dominiak G. Fuchs S. von Toth H. Grobecker Effects of nicotine and its major metabolites on blood pressure in anesthetized rats. Klin. Wochensch. 1 1985 90 92
20. M.L. Dubocovich Presynaptic α-adrenoceptors in the central nervous system. Ann. N. Y. Acad. Sci. 1 1984 7 25
21. 2-muscarinic receptors to excite rat locus coeruleus neurones. Br. J. Pharmacol. 1 1985 733 735
22. T.M. Egan R.A. North Actions of acetylcholine and nicotine on rat locus coeruleus neurons in vitro. Neuroscience 1 1986 565 571
23. F.S. Esch P.S. Keim E.C. Beattie R.W. Blacher A.R. Culwell T. Oltersdorf D. McClure P.J. Ward Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1 1990 1122 1124
24. E. Giacobini Quantitative determination of cholinesterase in individual sympathetic cells. J. Neurochem. 1 1957 234 244
25. E. Giacobini Cholinomimetic therapy of Alzheimer disease: does it slow down deterioration? G. Racagni N. Brunello S.Z. Langer Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. Int. Acad. Biomed. Drug Res. Vol. 7 1994 Karger New York 51 57
26. E. Giacobini G. Cuadra Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. E. Giacobini R. Becker Alzheimer Disease: Therapeutic Strategies 1994 Birkhauser Boston Cambridge, MA 155 171
27. E. Giacobini J. Zajicek Quantitative determination of acetylcholinesterase activity in individual nerve cells. Nature 1 1956 185 186
28. E. Giacobini F. Mori A. Buznikov R. Becker Cholinesterase inhibitors alter APP secretion and APP mRNA in rat cerebral cortex. Soc. Neuroscience Abstr. 1995 in press
29. A.M. Goldberg R.E. McCaman The determination of picomole amounts of acetylcholine in mammalian brain. J. Neurochem. 1 1973 1 8
30. J. Hardy R. Adolfsson I. Alafuzoff G. Bucht J. Marcusson P. Nyberg E. Perdahl P. Wester B. Winblad Transmitter deficits in Alzheimer's disease. Neurochem. Int. 1 1985 545 563
31. H. Hörtnagl P.E. Potter I. Hanin Effect of cholinergic deficit induced by ethylcholine aziridinium (AF64A) on noradrenergic and dopaminergic parameters in rat brain. Brain Res. 1 1987 75 84
32. B.P. Imbimbo P.E. Lucchelli A pharmacodynamic strategy to optimize the clinical response to eptastigmine (MF-201). E. Giacobini R. Becker Alzheimer Disease: Therapeutic Strategies 1994 Birkhauser Boston Cambridge, MA 103 107
33. G.M.M. Jones B.J. Sahakian The effects of nicotine in patients with dementia of the Alzheimer type. T. Kewitz T. Thomsen E. Bickel Pharmacological Interventions on Central Cholinergic Mechanisms in Senile Dementia 1989 Zuckschwerdt San Francisco, CA 89 96
34. J. Kang H-G. Lemaire A. Unterbeck J.M. Salbaum C.L. Master K-H. Grzeschil G. Multaup K. Beyreuther B. Muller-Hill The precursor of Alzheimer disease amyloid A4 protein resembles a cell-surface receptor. Nature 1 1987 733 736
35. M.J. Knapp D.S. Knopman P.R. Solomon W.W. Pendlebury C.S. Davis S.I. Gracon A 30-week randomized controlled trial of high-dose Tacrine in patients with Alzheimer's disease. J. Am. Med. Assoc. 1 1994 985 991
36. S.H. Koslow E. Giacobini An isotopic micromethod for the measurement of cholinesterase activity in individual cells. J. Neurochem. 1 1969 1523 1528
37. R. L'Heureux T. Dennis O. Curet B. Scatton Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: Effects of drugs affecting noradrenergic transmission. J. Neurochem. 1 1986 1794 1801
38. P.M. Lippiello W.S. Caldwell M.J. Marks A.C. Collins Development of nicotinic agonists for the treatment of Alzheimer's disease. E. Giacobini R. Becker Alzheimer Disease: Therapeutic Strategies 1994 Birkhauser Boston Cambridge, MA 186 190
39. P.M. Lippiello J.A. Gray S. Peters G. Grigoryan H. Hodges K. Summers E. Giacobini A.C. Collins Metanicotine: a nicotine analog with CNS selectivity - in vivo characterization. Soc. Neuroscience Abstr. 1995 in press
40. 2-adrenoceptors subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. 1 1992 410 416
41. R.E. McCaman S.A. Dewhurst Choline acetyltransferase in individual neurons of Aplysia californica. J. Neurochem. 1 1970 1421 1426
42. R.E. McCaman J.M. Hunt Microdetermination of choline acetylase in nervous tissue. J. Neurochem. 1 1965 253 259
43. E. Messamore U. Warpman N. Ogane E. Giacobini Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex. Neuropharmacology 1 1993 745 750
44. M.-M. Mesulam C. Geula Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J. Comp. Neurol. 1 1988 216 240
45. F. Mori G. Cuadra E. Williams E. Giacobini R. Becker Effects of metrifonate on acetylcholine and monoamine levels in rat cortex. Soc. Neuroscience Abstr. 20 1994 83 No. 40. 16
46. F. Mori C-C. Lai F. Fusi E. Giacobini Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. NeuroReport 1 1995 633 636
47. F. Moroni S. Tanganelli T. Antonelli V. Carlá C. Bianchi L. Beani Modulation of cortical acetylcholine and gamma-aminobutyric acid release in freely moving guinea pigs: effects of clonidine and other adrenergic drugs. J. Pharmacol. Exp. Ther. 1 1983 230 236
48. P.A. Newhouse T. Sunderland K. Thompson P.N. Tariot H. Weingartner E.R. Mueller R.M. Cohen D.L. Murphy Intravenous nicotine in a patient with Alzheimer's disease. Am. J. Psychiatr. 1 1986 1494 1495
49. P. Newhouse T. Sunderland P. Narang A.M. Mellow J.B. Fertig B.A. Lawlor D.L. Murphy Neuroendocrine, physiologic and behavioral responses following intravenous nicotine in non-smoking healthy volunteers and patients with Alzheimer's disease. Psychoneuroendocrinology 1 1990 471 484
50. R.M. Nitsch J.H. Growdon Role of neurotransmission in the regulation of amyloid beta-protein precursor processing. Biochem. Pharmacol. 1 1994 1275 1284
51. R.M. Nitsch B.E. Slack R.J. Wurtman J.H. Growdon Release of Alzheimer precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1 1992 304 307
52. R.M. Nitsch S.A. Farber J.H. Growdon R.J. Wurtman Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc. Natl. Acad. Sci. USA 1 1993 191 193
53. 2-adrenergic agents. J. Neurochem. 1 1991 1387 1393
54. J.G. Parnavelas Neurotransmitters in the cerebral cortex. H.B.M. Uylings C.G. Van Eden J.P.C. De Bruin M.A. Corner M.G.P. Feenstra Progress in Brain Research Vol. 85 1990 Elsevier Amsterdam 13 29
55. E.K. Perry J.A. Court S. Lloyd M. Johnson M.H. Griffiths D. Spurden M.A. Piggott J. Turner R.H. Perry Beta-amyloidosis in normal aging and transmitter signalling in human temporal lobe. J.H. Growdon R.M. Nitsch S. Corkin R.J. Wurtman The Neurobiology of Alzheimer Disease 1995 Center for Brain Sciences Zurich 451 455
56. J.A. Pratt I.P. Stolerman H.S. Garcha V. Giardini C. Feyerabend Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor. Psychopharmacology 1 1983 291 296
57. K.A. Roth S.L. McIntire J.D. Barchas Nicotiniccatecholaminergic interactions in rat brain: evidence for cholinergic nicotinic and muscarinic interactions with hypothalamic epinephrine. J. Pharmacol. Exp. Ther. 1 1982 416 420
58. D.B. Rye B.H. Wainer M.-M. Mesulam E.J. Mufson C.B. Saper Cortical projections arising from the basal forebrain: a study of cholinergic and noncholinergic components employing combined retrograde tracing and immunohistochemical localization of choline acetyltransferase. Neuroscience 1 1984 627 643
59. A.C. Santucci V. Haroutunian K.L. Davis Pharmacological alleviation of combined cholinergic - noradrenergic lesion-induced memory deficits in rats. Clin. Neuropharmacol. 1 1991 1 8
60. H. Schröder A. Wevers C. Birtsch Nicotinic receptors in human brain. E. Giacobini R. Becker Alzheimer Disease: Therapeutic Strategies 1994 Birkhauser Boston Cambridge, MA 181 185
61. 3-H]-nicotine. J. Neurochem. 1 1985 604 610
62. S.S. Sisodia E.H. Koo K. Beyreuther A. Unterbeck D.L. Price Evidence that beta amyloid protein in Alzheimer disease is not derived by normal processing. Science 1 1990 492 495
63. 4 allele. Neurosci. Lett. 1 1995 79 82
64. K.L. Summers E. Giacobini Effects of local and repeated systemic administration of (-)nicotine on release of acetylcholine, norepinephrine, dopamine and serotonin in rat cortex. J. Neurosci. Res. 1 1995 683 689
65. K.L. Summers G. Cuadra D. Naritoku E. Giacobini Effects of nicotine on levels of acetylcholine and biogenic amines in rat cortex. Drug Dev. Res. 1 1994 108 119
66. K.L. Summers P.M. Lippiello S. Verhulst E. Giacobini 5-Fluoronicotine, noranhydroeccgonine and pyridylmehtylpyrrolidine release acetylcholine and biogenic amines in rat cortex in vivo. Neurochem. Res. 1 1995 1089 1094
67. R.D. Terry E. Masliah D.P. Salmon N. Butters R. De Teresa R. Hill L.A. Hansen R. Katzman Physical basis of cognitive alterations in Alzheimer disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1 1991 572 580
68. 2-adrenoceptors of endogenous noradrenaline and dopamine release from slices of rat hypothalamus. Life Sci. 1 1983 371 376
69. M.J. van Veldhuizen M.G. Feenestra R.P. Heinsbroek G.J. Boer In vivo microdialysis of noradrenaline overflow: effects of alpha-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves. Br. J. Pharmacol. 1 1993 655 660
70. E.S. Vizi Modulation of cortical release of acetylcholine by noradrenaline released from nerves arising from the rat locus coeruleus. Neuroscience 1 1980 2139 2144
71. D.M. Warburton Nicotine as a cognitive enhancer. I.I. Yamashita M. Toru A.J. Copen Clinical Neuropharmacology Vol. 13 1990 Raven Press New York 579 580
72. R.A. Wise Catecholamine theories of reward: a critical review. Brain Res. 1 1978 215 247